DK1420769T3 - Lipid profil modulation med steroider og PPAR alpha agonister - Google Patents
Lipid profil modulation med steroider og PPAR alpha agonisterInfo
- Publication number
- DK1420769T3 DK1420769T3 DK02707001T DK02707001T DK1420769T3 DK 1420769 T3 DK1420769 T3 DK 1420769T3 DK 02707001 T DK02707001 T DK 02707001T DK 02707001 T DK02707001 T DK 02707001T DK 1420769 T3 DK1420769 T3 DK 1420769T3
- Authority
- DK
- Denmark
- Prior art keywords
- steroids
- lipid profile
- ppar alpha
- alpha agonists
- profile modulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0107383.2A GB0107383D0 (en) | 2001-03-23 | 2001-03-23 | Lipid profile modulation |
| PCT/GB2002/001457 WO2002076435A2 (en) | 2001-03-23 | 2002-03-25 | Lipid profile modulation with steroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1420769T3 true DK1420769T3 (da) | 2008-09-29 |
Family
ID=9911465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02707001T DK1420769T3 (da) | 2001-03-23 | 2002-03-25 | Lipid profil modulation med steroider og PPAR alpha agonister |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050032761A1 (da) |
| EP (1) | EP1420769B1 (da) |
| JP (1) | JP2004528308A (da) |
| AT (1) | ATE397922T1 (da) |
| AU (1) | AU2002241160A1 (da) |
| CA (1) | CA2441834C (da) |
| DE (1) | DE60227080D1 (da) |
| DK (1) | DK1420769T3 (da) |
| ES (1) | ES2307729T3 (da) |
| GB (2) | GB0107383D0 (da) |
| PT (1) | PT1420769E (da) |
| WO (1) | WO2002076435A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| JP2006522744A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
| EP1854487A3 (en) * | 2003-04-11 | 2010-09-22 | High Point Pharmaceuticals, LLC | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| PL1663185T3 (pl) * | 2003-09-22 | 2009-06-30 | Onepharm Res & Development Gmbh | Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego |
| EP1928840B1 (en) | 2005-04-05 | 2011-08-10 | F. Hoffmann-La Roche AG | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| JP4276280B2 (ja) | 2005-11-21 | 2009-06-10 | 塩野義製薬株式会社 | Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
| KR101081293B1 (ko) | 2006-01-18 | 2011-11-08 | 에프. 호프만-라 로슈 아게 | 11 베타-에이치에스디1 억제제로서 티아졸 |
| JP2009531712A (ja) * | 2006-03-23 | 2009-09-03 | デ グスマン ブレイヤー、エメリタ | アポリポタンパク質フィンガープリント技術 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| DK2163543T3 (da) | 2007-05-18 | 2015-04-27 | Shionogi & Co | Nitrogenholdigt heterocyklisk derivat med 11beta-hydroxysteroiddehydrogenase-type 1-inhibitorisk aktivitet |
| CN102223797A (zh) | 2008-11-21 | 2011-10-19 | 高点制药有限责任公司 | 金刚烷基苯甲酰胺化合物 |
| WO2011061749A2 (en) * | 2009-11-19 | 2011-05-26 | Ganga Raju Gokaraju | Agents derived from holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases |
| WO2012015715A1 (en) | 2010-07-27 | 2012-02-02 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators |
| US9781909B2 (en) * | 2013-07-17 | 2017-10-10 | University Of Manitoba | Mito-Ob: a transgenic mouse model for obesity |
| FR3035326B1 (fr) * | 2015-04-21 | 2017-05-12 | Pf Medicament | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| US10226474B2 (en) * | 2017-01-09 | 2019-03-12 | Temple University—Of The Commonwealth Sytem Of Higher Education | Methods and compositions for treatment of non-alcoholic steatohepatitis |
| KR102177304B1 (ko) | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| EP3883578A4 (en) * | 2018-11-20 | 2022-07-27 | Sparrow Pharmaceuticals, Inc. | METHOD OF ADMINISTRATION OF CORTICOSTEROIDS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
| US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
| GB9517622D0 (en) * | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
| US5985861A (en) * | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
| US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| JP2004502432A (ja) * | 2000-07-05 | 2004-01-29 | バイエル アクチェンゲゼルシャフト | ヒト１１β−ヒドロキシステロイドデヒドロゲナーゼ１様酵素の調節 |
| GB0105772D0 (en) * | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
-
2001
- 2001-03-23 GB GBGB0107383.2A patent/GB0107383D0/en not_active Ceased
-
2002
- 2002-03-25 WO PCT/GB2002/001457 patent/WO2002076435A2/en active IP Right Grant
- 2002-03-25 AT AT02707001T patent/ATE397922T1/de active
- 2002-03-25 ES ES02707001T patent/ES2307729T3/es not_active Expired - Lifetime
- 2002-03-25 PT PT02707001T patent/PT1420769E/pt unknown
- 2002-03-25 AU AU2002241160A patent/AU2002241160A1/en not_active Abandoned
- 2002-03-25 DK DK02707001T patent/DK1420769T3/da active
- 2002-03-25 JP JP2002574951A patent/JP2004528308A/ja active Pending
- 2002-03-25 EP EP02707001A patent/EP1420769B1/en not_active Expired - Lifetime
- 2002-03-25 DE DE60227080T patent/DE60227080D1/de not_active Expired - Lifetime
- 2002-03-25 CA CA2441834A patent/CA2441834C/en not_active Expired - Fee Related
- 2002-03-25 GB GB0323962A patent/GB2390367B/en not_active Expired - Fee Related
-
2003
- 2003-09-23 US US10/668,564 patent/US20050032761A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2441834A1 (en) | 2002-10-03 |
| US20050032761A1 (en) | 2005-02-10 |
| EP1420769B1 (en) | 2008-06-11 |
| GB0323962D0 (en) | 2003-11-19 |
| EP1420769A2 (en) | 2004-05-26 |
| WO2002076435A2 (en) | 2002-10-03 |
| GB2390367B (en) | 2005-04-13 |
| ATE397922T1 (de) | 2008-07-15 |
| JP2004528308A (ja) | 2004-09-16 |
| PT1420769E (pt) | 2008-08-05 |
| GB0107383D0 (en) | 2001-05-16 |
| DE60227080D1 (de) | 2008-07-24 |
| CA2441834C (en) | 2011-01-25 |
| ES2307729T3 (es) | 2008-12-01 |
| WO2002076435A3 (en) | 2004-03-18 |
| GB2390367A (en) | 2004-01-07 |
| AU2002241160A1 (en) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1420769T3 (da) | Lipid profil modulation med steroider og PPAR alpha agonister | |
| DK1098649T3 (da) | Fremgangsmåde til stabilisering af farmaceutiske sammensætninger med speciel anvendelse af antioxidant | |
| NO20040865L (no) | Friksjon reduserende sammensetning og metode | |
| NO20023531D0 (no) | Tetning for kompressor og sentrifugalkompressor utstyrt med slik tetning | |
| NO20062649L (no) | Biarylsulfonamider og metoder for anvendelse av disse | |
| BR0215405A (pt) | Composições e processos de uso de collajolie | |
| DE602004019812D1 (de) | Marker für neuromyelitis optica | |
| IS7858A (is) | Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD) | |
| CY1113651T1 (el) | Αντιφλεγμονωδη σκευασματα | |
| WO2003103571A3 (en) | VACCINES AGAINST FLAVIVIRUSES | |
| NO20044898L (no) | Nye etonogestrel estere | |
| NO20040542L (no) | Fremgangsmate for installasjon av en ankerline og kobling for bruk i fremgangsmaten | |
| DK1509492T3 (da) | Sedative hypnotiske midler med kort virkningsvarighed til anæstesi og sedation | |
| NO20040055L (no) | Sarbandasje | |
| ITMI20021822A1 (it) | Manicotto elastico e procedimento per la fabbricazione di un manicotto elastico | |
| DE60239534D1 (de) | Mobilesendgerät mit Bidirektioneler Betriebsart und Verfahren für dessen Herstellung | |
| RS51138B (sr) | S-mirtazapin za lečenje nastupa vreline (valunga) | |
| CY1113083T1 (el) | Ασβεστιολυτικες ενωσεις | |
| AU2003251529A8 (en) | Planetarium and point light source for the use in same | |
| DE60305522D1 (de) | Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer | |
| NO20043107L (no) | Bronnsementeringsbestanddeler for kalde omgivelser | |
| SE0301650D0 (sv) | Novel compounds | |
| UY28531A1 (es) | Composición líquida biologicamente estable de fviii, de fww o del complejo fviii/fww humanos | |
| BR0312184B1 (pt) | terminal para zÍper e zÍper tendo o mesmo | |
| NO20033747D0 (no) | Fremgangsmåte ved sementering i en underjordisk sone og brönnsement til bruk ved utförelse av fremgangsmåten |